Immunization, Hib3 in Guinea-Bissau
Guinea-Bissau: Immunization, Hib3 was 68.0% in 2024. ▼ Falling
Immunization, Hib3 in Guinea-Bissau, 2009–2024
Source: WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/). Measured in % of children ages 12-23 months.
Analysis
In 2024, immunization, hib3 in Guinea-Bissau stood at 68.0%.
The figure is down 8.1% on the previous year and down 20.9% over ten years.
Over the whole period, immunization, hib3 in Guinea-Bissau peaked at 89.0% in 2011 and was at its lowest, 67.0%, in 2021.
Guinea-Bissau ranks 171st of 191 countries on this measure, in the bottom quarter.
The long-run direction has been consistently falling across the 16 years of available data.
Immunization, Hib3 in Guinea-Bissau, year by year
| Year | % of children ages 12-23 months | Change |
|---|---|---|
| 2009 | 80.0% | — |
| 2010 | 86.0% | +7.5% |
| 2011 | 89.0% | +3.5% |
| 2012 | 87.0% | -2.2% |
| 2013 | 87.0% | +0.0% |
| 2014 | 86.0% | -1.1% |
| 2015 | 86.0% | +0.0% |
| 2016 | 85.0% | -1.2% |
| 2017 | 79.0% | -7.1% |
| 2018 | 82.0% | +3.8% |
| 2019 | 78.0% | -4.9% |
| 2020 | 74.0% | -5.1% |
| 2021 | 67.0% | -9.5% |
| 2022 | 74.0% | +10.4% |
| 2023 | 74.0% | +0.0% |
| 2024 | 68.0% | -8.1% |
Guinea-Bissau compared with similar countries
- Guinea-Bissau's 68.0% is below the median for low income countries, which is 73.0%, 93% of the median. (25 countries reporting)
- Guinea-Bissau's 68.0% is below the median for Sub-Saharan Africa, which is 82.5%, 82% of the median. (48 countries reporting)
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 80.0% | 80.0% | 80.0% | 1 |
| 2010s | 84.5% | 78.0% | 89.0% | 10 |
| 2020s | 71.4% | 67.0% | 74.0% | 5 |
Countries ranked near Guinea-Bissau
More health data for Guinea-Bissau
- Un projection of annual infant deaths, annual growth rate -1.67 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate 0.7721 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 1,070 deaths per 1,000 people (2090)
- Number of infants who die before age 1 941 deaths (2100)
- Neonatal tetanus - number of reported cases, gaps filled 0 (2025)
- Population ages 00-04, female, annual growth rate 0.899 % change on previous year (2025)
- Population ages 00-04, female, per unit of GDP 0.0001 units per US$ of GDP (2025)
- Population ages 00-04, female, per capita 0.0664 units per person (2025)
- Population ages 00-04, male, annual growth rate 0.8987 % change on previous year (2025)
- Population ages 00-04, male, per unit of GDP 0.0001 units per US$ of GDP (2025)
Frequently asked questions
- What is immunization, hib3 in Guinea-Bissau?
- Immunization, hib3 in Guinea-Bissau was 68.0% in 2024, according to WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/).
- What is the highest immunization, hib3 recorded in Guinea-Bissau?
- The highest recorded value was 89.0% in 2011.
- What is the lowest immunization, hib3 recorded in Guinea-Bissau?
- The lowest recorded value was 67.0% in 2021.
- How does Guinea-Bissau rank for immunization, hib3?
- Guinea-Bissau ranks 171st out of 191 countries with data for 2024.
- Is immunization, hib3 rising or falling in Guinea-Bissau?
- Over the last ten years it is down 20.9%. The long-run trend across the full record is falling.
- Where does this Guinea-Bissau data come from?
- The figures come from WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/), published as part of Immunization, Hib3 (% of children ages 12-23 months). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 16 observations, free to reuse under CC BY 4.0 (World Bank Open Data).
About this data
Child immunization, Hib3, measures the percentage of children ages 12-23 months who received Hib3 vaccinations before 12 months or at any time before the survey. A child is considered adequately immunized against Hib3 after receiving three doses of Haemophilus influenzae type b vaccine.